Allogene Therapeutics Inc ALLO:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 2:06 PM EDT
2.94quote price arrow up+0.02 (+0.68%)
Volume
699,040
52 week range
2.23 - 6.89
Loading...
  • Open3.07
  • Day High3.09
  • Day Low2.92
  • Prev Close2.92
  • 52 Week High6.89
  • 52 Week High Date05/15/23
  • 52 Week Low2.23
  • 52 Week Low Date12/01/23

Key Stats

  • Market Cap501.926M
  • Shares Out170.72M
  • 10 Day Average Volume2.18M
  • Dividend-
  • Dividend Yield-
  • Beta0.88
  • YTD % Change-8.72

KEY STATS

  • Open3.07
  • Day High3.09
  • Day Low2.92
  • Prev Close2.92
  • 52 Week High6.89
  • 52 Week High Date05/15/23
  • 52 Week Low2.23
  • 52 Week Low Date12/01/23
  • Market Cap501.926M
  • Shares Out170.72M
  • 10 Day Average Volume2.18M
  • Dividend-
  • Dividend Yield-
  • Beta0.88
  • YTD % Change-8.72

RATIOS/PROFITABILITY

  • EPS (TTM)-2.09
  • P/E (TTM)-1.41
  • Fwd P/E (NTM)-1.83
  • EBITDA (TTM)-300.292M
  • ROE (TTM)-55.51%
  • Revenue (TTM)94,999.999
  • Gross Margin (TTM)-
  • Net Margin (TTM)-344,489.50%
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date07/31/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Allogene Therapeutics Inc

 

Profile

MORE
Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company. The Company is focused on development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. It is focused on four core programs: Large B-Cell Lymphoma (LBCL), Chronic Lymphocytic Leukemia (CLL), Autoimmune Disease and Renal Cell Carcinoma. It is developing a pipeline of multiple allogeneic chimeric antigen receptor (CAR) T cell product...
Arie Belldegrun M.D.
Executive Chairman of the Board
David Chang M.D., Ph.D.
President, Chief Executive Officer, Co-Founder, Director
Geoffrey Parker
Chief Financial Officer, Executive Vice President, Principal Financial Officer, and Principal Accounting Officer
Timothy Moore
Executive Vice President, Chief Technical Officer
Zachary Roberts M.D., Ph.D.
Executive Vice President - Research and Development, Chief Medical Officer
Earl Douglas Esq.
General Counsel
Address
210 East Grand Avenue
South San Francisco, CA
94080
United States

Top Peers

SYMBOLLASTCHG%CHG
ATXS
Astria Therapeutics Inc
9.40-0.10-1.05%
CMPS
Compass Pathways PLC
8.32-0.16-1.89%
CELC
Celcuity Inc
17.61+1.31+8.04%
NKTX
Nkarta Inc
7.71+0.21+2.87%
LBPH
Longboard Pharmaceuticals Inc
22.49+0.53+2.41%